Accelerating research

and development of

new antibiotics and

alternatives

News

NADP News

British Biotech Receives €52M Boost to Beat Antimicrobial Resistance with New Antibiotic

13 September 2017

In a recent press release Summit Therapeutics announced they received the BARDA Contract worth $62 mil. for the development of a new treatment against Clostridium difficile infections.

Read more

EU Joint action on antimicrobial resistance launched

13 September 2017

A joint action on antimicrobial resistance and healthcare-associated infections (EU-JAMRAI), bringing together member states, international organizations, institutes and universities to tackle the AMR threat was launched on 13 September, at the French Ministry of Health in Paris.

Read more

Researchers break resistant bacteria’s defence against antibiotics

11 September 2017

Researchers from the University of Copenhagen have discovered a method with which antibiotics can have an effect on pathogenic bacteria that are naturally resistant to treatment. In brief, the method targets the bacterium’s energy centre, making it easier for antibiotics to penetrate the bacteria cell and kill it.

Read more

CEO Madam Therapeutics interviewed on urgent need for antimicrobials

6 September 2017

On September 1st, Remko van Leeuwen CEO of Madam Therapeutics, gave a pitch and was interviewed on the “Zaken doen met” radioshow on the Dutch Radio Station BNR.

Read more

More than EUR 56 million raised to fund initiative to fight antibiotic resistance

5 September 2017

Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.

Read more

Events Calendar

Upcoming events

A list of upcoming events, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.

Read More